The Novel BCR-ABL and FLT3 Inhibitor Ponatinib Is a Potent Inhibitor of the MDR-Associated ATP-Binding Cassette Transporter ABCG2
Rupashree Sen(University of Maryland, Baltimore), Maria R. Baer(University of Maryland, Baltimore), Zhe‐Sheng Chen(New York College of Traditional Chinese Medicine), Jasjeet Bhullar(University of Maryland, Baltimore), Suneet Shukla(National Cancer Institute), Suresh V. Ambudkar(National Institutes of Health), Ling Cai(The University of Texas Southwestern Medical Center), Hong-Bin Fang(University of Maryland, Baltimore), Karthika Natarajan(Center for Drug Evaluation and Research)
Cited by 91
Related Papers
Microbiota in health and diseases
|Signal Transduction and Targeted Therapy|2022|2.9k
Lactate Metabolism in Human Lung Tumors
|Cell|2017|1.3k
Gilteritinib or Chemotherapy for Relapsed or Refractory <i>FLT3</i> -Mutated AML
|New England Journal of Medicine|2019|1.3k